Sukumar Nagendran
2022 - Taysha Gene Therapies
In 2022, Sukumar Nagendran earned a total compensation of $1.4M as President and Head of Research and Development at Taysha Gene Therapies.
Compensation breakdown
| Option Awards | $1,285,910 |
|---|---|
| Salary | $23,542 |
| Other | $54,093 |
| Total | $1,363,545 |
Nagendran received $1.3M in option awards, accounting for 94% of the total pay in 2022.
Nagendran also received $23.5K in salary and $54.1K in other compensation.
Rankings
In 2022, Sukumar Nagendran's compensation ranked 2,432nd out of 5,760 executives tracked by ExecPay. In other words, Nagendran earned more than 57.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,432 out of 5,760 | 58th |
Division Manufacturing | 1,332 out of 3,136 | 58th |
Major group Chemicals And Allied Products | 600 out of 1,422 | 58th |
Industry group Drugs | 554 out of 1,323 | 58th |
Industry Biological Products, Except Diagnostic Substances | 137 out of 291 | 53rd |
Source: SEC filing on May 8, 2023.
Nagendran's colleagues
We found three more compensation records of executives who worked with Sukumar Nagendran at Taysha Gene Therapies in 2022.